New combo aims to control Hard-to-Treat sarcomas
Disease control
Terminated
This study tests a combination of fruquintinib (a targeted therapy) and an immunotherapy drug for people with advanced or unresectable bone and soft tissue sarcoma that has not responded to standard treatments. The goal is to see if this combination can slow tumor growth or shrin…
Phase: PHASE2 • Sponsor: Shanghai 6th People's Hospital • Aim: Disease control
Last updated Jun 22, 2026 11:57 UTC